Search
Turn Therapeutics Ord Shs
TTRXAdd to Watchlist
13.260USD
-0.250-1.85%
Close 09-24 16:00（ET）
395.02MMarket Cap
LossP/E TTM
TTRX Analyst Recommendation Trends
In the current month, TTRX has received 1 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. TTRX average Analyst price target in the last month is 18.000.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
1
1
0
0
0
0
0
0
1
1
1
1
2
2
2
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2
2
1
1
2
2
2
2
Financial Forecasting
Based on analysts' estimates, TTRX EPS is projected to reach -0.090 in FY2026Q3, following reported EPS of -0.196 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.04
-0.03
-0.03
-0.09
-0.08
Actual
0.01
-0.03
-0.20
--
--
Surprise
+126.03%
-31.76%
-685.52%
--
--
FAQs
How have Turn Therapeutics Ord ShsTTRX's recent earnings per share performed?
The market expectation was USD -0.20, while Turn Therapeutics Ord ShsTTRX's earnings per share (EPS) for the previous quarter was USD -0.03. EPS for the next quarter is expected at USD -0.09.
What is the analyst rating for Turn Therapeutics Ord Shs?
Based on the ratings of Turn Therapeutics Ord Shs's stock from 2 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.